Fmc FMC

NYSE FMC

$12.28 -0.53 (-4.10%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap1.54 Bn

P/E-0.56

P/S0.48

Div. Yield0.11

Total Debt (Qtr)4.29 Bn

Revenue Growth (1y) (Qtr)-17.46

Add ratio to table…

About

FMC Corporation is a global agricultural sciences company dedicated to providing farmers innovative solutions that increase the productivity and resilience of their land. The company focuses on discovering and developing insecticide, herbicide and fungicide active ingredients, product formulations and technologies that are better for the planet. It maintains an industry leading development pipeline that includes novel biologicals and precision technologies. FMC Corporation…

FMC Corporation generates revenue primarily through the sale of its crop protection chemicals and plant health products to farmers and agricultural businesses. The company’s product portfolio is divided into insecticides, herbicides, fungicides and a growing plant health segment that includes biologicals, crop nutrition and seed treatment solutions. In 2024 the diamide insecticide Rynaxypyr contributed approximately $1.0 billion in sales while the diamide insecticide Cyazypyr contributed approximately $0.5 billion. Additional revenue is derived from herbicide brands such as Isoflex and Dodhylex, fungicide brands including fluindapyr and Onsuva, and a range of biological and seed treatment offerings. The company distributes its products through its own sales force, independent distributors, retailers, cooperatives and directly to large growers in markets such as Brazil. FMC Corporation also offers digital tools like the Arc farm intelligence platform which is available in over 25 countries and covers more than 20 million acres, providing another avenue for revenue through technology services.

FMC Corporation holds a tier one position as the fifth largest global innovator in the agrochemicals and crop protection market. According to industry data herbicides represent about 41%, insecticides about 29% and fungicides about 27% of the global agricultural crop protection market value. The five leading companies including FMC, ChemChina (owner of Syngenta Group), Bayer AG, BASF AG and Corteva Agriscience together account for roughly 72% of global sales. Competitive advantages stem from a robust innovation pipeline, a balanced geographic footprint, a diverse crop portfolio and a low cost manufacturing model. The company also benefits from an extensive intellectual property estate with over 170 granted U. S. patents and more than 2,500 granted foreign patents as of December 2024, which helps protect its key products and supports long term growth.

FMC Corporation serves a broad base of farmers that produce food, feed, fiber and fuel for a growing global population. Its customers include producers of major crops such as soybean, corn, cotton, rice, sugarcane and various fruits and vegetables across North America, Latin America, Europe, Middle East, Africa and Asia. The company reaches these growers through its own sales organization, independent distributors, retailers and agricultural cooperatives, and also sells directly to large scale operations in countries like Brazil. While specific customer names are not disclosed in the filing, the diversified nature of its client base reduces reliance on any single buyer and supports stable demand for its product lines.

Investment Thesis

▲ Bull case

The company’s plan to reduce debt by approximately $1 billion in 2026 through the sale of its India commercial business and other noncore assets will materially lower leverage and interest costs. The definitive agreement for the India transaction at $252 million provides near term cash that is earmarked for debt paydown directly improving the net debt to EBITDA ratio. Additional proceeds from licensing of new active ingredients and the divestiture of noncore molecules or real estate will further deleverage the balance sheet beyond the stated target. A stronger balance sheet reduces financial risk and creates capacity for future investments in high growth products a factor that the market may be underestimating given the current focus on near term earnings pressure.
The shift of production from higher cost plants to lower cost sources in Asia scheduled for completion in Q1 FY27 will lower the cost base of the non diamide core portfolio. This structural cost advantage will help offset pricing pressure from generic competitors and improve margin stability over the medium term. Early actions already taken to restructure the Asian footprint in anticipation of the India sale have begun to generate savings that are not yet fully reflected in current results. As these savings accumulate the company’s core business could become more competitive than the market expects supporting a re rating of its valuation multiples.
Sales of the company’s new active ingredients including Isoflex active fluindapyr and Dodhylex active doubled year over year in Q1 FY26 indicating strong early demand. Isoflex active received regulatory approval in the EU marking the first new herbicide approval in the region since 2019 and opening access to more than 55 million planted hectares of cereals corn oseedrape and potato. Preregistration exemption requests in Italy Germany France and Spain could accelerate revenue recognition in the second half of FY26 providing an upside to current guidance. The combination of regulatory progress and farmer adoption suggests that the new product pipeline will become a material driver of sales and earnings growth beyond the near term a catalyst that may be underappreciated.
Despite the expiration of the Rynaxypyr patent the company is pursuing a post patent strategy that focuses on maintaining branded earnings flat while gaining volume in high load formulations and differentiated mixtures. Early signals show positive reaction to price repositioning with strong volume growth in high load products and some initial share gains from other classes of insecticides. Ongoing cost improvements are supporting margins in line with expectations and further cost reduction opportunities could enhance competitiveness. This approach may allow the Rynaxypyr business to generate stable earnings even as generic competition intensifies a dynamic that the market may be overlooking when assessing long term profitability.
Management highlighted that by the end of April FY26 orders already represented 32% of H2 direct sales in Brazil with expectations to reach about 50% by the end of June. This order book strength reflects the effectiveness of the new direct sales organization put in place in FY25 and now operating at full capacity. The volume contribution from new active ingredients and the non diamide core in Brazil is expected to drive a significant sequential improvement in sales from H1 to H2 FY26. If the order trajectory continues as indicated the second half could exceed current guidance providing an upside to earnings that is not fully priced in.

The company’s plan to reduce debt by approximately $1 billion in 2026 through the sale of its India commercial business and other noncore assets will materially lower leverage and interest costs. The definitive agreement for the India transaction at $252 million provides near term cash that is earmarked for debt paydown directly improving the net debt to EBITDA ratio. Additional proceeds from licensing of new active ingredients and the divestiture of noncore molecules or real estate will further deleverage the balance sheet beyond the stated target. A stronger balance sheet reduces financial risk and creates capacity for future investments in high growth products a factor that the market may be underestimating given the current focus on near term earnings pressure.
The shift of production from higher cost plants to lower cost sources in Asia scheduled for completion in Q1 FY27 will lower the cost base of the non diamide core portfolio. This structural cost advantage will help offset pricing pressure from generic competitors and improve margin stability over the medium term. Early actions already taken to restructure the Asian footprint in anticipation of the India sale have begun to generate savings that are not yet fully reflected in current results. As these savings accumulate the company’s core business could become more competitive than the market expects supporting a re rating of its valuation multiples.
Sales of the company’s new active ingredients including Isoflex active fluindapyr and Dodhylex active doubled year over year in Q1 FY26 indicating strong early demand. Isoflex active received regulatory approval in the EU marking the first new herbicide approval in the region since 2019 and opening access to more than 55 million planted hectares of cereals corn oseedrape and potato. Preregistration exemption requests in Italy Germany France and Spain could accelerate revenue recognition in the second half of FY26 providing an upside to current guidance. The combination of regulatory progress and farmer adoption suggests that the new product pipeline will become a material driver of sales and earnings growth beyond the near term a catalyst that may be underappreciated.
Despite the expiration of the Rynaxypyr patent the company is pursuing a post patent strategy that focuses on maintaining branded earnings flat while gaining volume in high load formulations and differentiated mixtures. Early signals show positive reaction to price repositioning with strong volume growth in high load products and some initial share gains from other classes of insecticides. Ongoing cost improvements are supporting margins in line with expectations and further cost reduction opportunities could enhance competitiveness. This approach may allow the Rynaxypyr business to generate stable earnings even as generic competition intensifies a dynamic that the market may be overlooking when assessing long term profitability.
Management highlighted that by the end of April FY26 orders already represented 32% of H2 direct sales in Brazil with expectations to reach about 50% by the end of June. This order book strength reflects the effectiveness of the new direct sales organization put in place in FY25 and now operating at full capacity. The volume contribution from new active ingredients and the non diamide core in Brazil is expected to drive a significant sequential improvement in sales from H1 to H2 FY26. If the order trajectory continues as indicated the second half could exceed current guidance providing an upside to earnings that is not fully priced in.

▼ Bear case

Despite the target to reduce debt by approximately $1 billion the company’s gross debt remains around $4.5 billion and net debt stands at $4.1 billion resulting in a net debt to EBITDA ratio of 5.2 times. Interest expense increased in Q1 FY26 to $64.8 million reflecting higher rates on subordinated debt and short term borrowing costs and is projected to rise to $255 million to $275 million for the full year. This elevated interest burden will consume a significant portion of EBITDA limiting free cash flow generation and constraining financial flexibility. If market conditions deteriorate and refinancing terms become less favorable the leverage could become a material risk that the market may be underpricing.
The removal of diamide partner sales and the divestiture of the India commercial business are expected to reduce reported revenue even though the underlying core business may show only modest change. Management noted that excluding these two factors Q2 results would be similar to the prior year indicating that the base business faces persistent pressures. Ongoing generic competition and a competitive market for legacy core products continue to exert downward pressure on pricing and limit top line growth. Unless the company can offset these losses with faster than anticipated growth from new products the revenue trajectory may remain weaker than projected.
The growth of new active ingredients such as fluindapyr and Dodhylex is contingent upon obtaining regulatory registrations in multiple jurisdictions. The company disclosed that there are nineteen registrations pending for fluindapyr alone and similar processes are required for Dodhylex in Asia. Delays in these approvals could postpone the expected revenue contribution and slow the ramp up of sales growth that management is counting on for FY27 and beyond. The market may be assuming a smoother registration path than what the historical variability in agrochemical approvals suggests creating a potential downside risk.
Management acknowledged that higher energy transportation and petrochemical costs linked to the Iran conflict and tariff environment are beginning to flow through to product costs. While the company currently assumes that these cost pressures will be offset by potential tariff recoveries the outcome remains highly uncertain. If the tariff recovery mechanism does not materialize or if the geopolitical situation worsens input costs could rise faster than anticipated squeezing margins. This margin pressure could counteract any benefits from cost reduction initiatives and weigh on profitability.
The company forecasts full year FY26 free cash flow to range from negative $65 million to positive $65 million implying a breakeven midpoint. This range incorporates approximately $150 million of restructuring cash spending which could vary depending on the timing and magnitude of severance and asset write downs. If restructuring costs exceed expectations or if working capital improvements fall short the free cash flow outcome could remain negative throughout the year. A sustained negative free cash flow position would increase reliance on external financing and could constrain strategic initiatives.

Despite the target to reduce debt by approximately $1 billion the company’s gross debt remains around $4.5 billion and net debt stands at $4.1 billion resulting in a net debt to EBITDA ratio of 5.2 times. Interest expense increased in Q1 FY26 to $64.8 million reflecting higher rates on subordinated debt and short term borrowing costs and is projected to rise to $255 million to $275 million for the full year. This elevated interest burden will consume a significant portion of EBITDA limiting free cash flow generation and constraining financial flexibility. If market conditions deteriorate and refinancing terms become less favorable the leverage could become a material risk that the market may be underpricing.
The removal of diamide partner sales and the divestiture of the India commercial business are expected to reduce reported revenue even though the underlying core business may show only modest change. Management noted that excluding these two factors Q2 results would be similar to the prior year indicating that the base business faces persistent pressures. Ongoing generic competition and a competitive market for legacy core products continue to exert downward pressure on pricing and limit top line growth. Unless the company can offset these losses with faster than anticipated growth from new products the revenue trajectory may remain weaker than projected.
The growth of new active ingredients such as fluindapyr and Dodhylex is contingent upon obtaining regulatory registrations in multiple jurisdictions. The company disclosed that there are nineteen registrations pending for fluindapyr alone and similar processes are required for Dodhylex in Asia. Delays in these approvals could postpone the expected revenue contribution and slow the ramp up of sales growth that management is counting on for FY27 and beyond. The market may be assuming a smoother registration path than what the historical variability in agrochemical approvals suggests creating a potential downside risk.
Management acknowledged that higher energy transportation and petrochemical costs linked to the Iran conflict and tariff environment are beginning to flow through to product costs. While the company currently assumes that these cost pressures will be offset by potential tariff recoveries the outcome remains highly uncertain. If the tariff recovery mechanism does not materialize or if the geopolitical situation worsens input costs could rise faster than anticipated squeezing margins. This margin pressure could counteract any benefits from cost reduction initiatives and weigh on profitability.
The company forecasts full year FY26 free cash flow to range from negative $65 million to positive $65 million implying a breakeven midpoint. This range incorporates approximately $150 million of restructuring cash spending which could vary depending on the timing and magnitude of severance and asset write downs. If restructuring costs exceed expectations or if working capital improvements fall short the free cash flow outcome could remain negative throughout the year. A sustained negative free cash flow position would increase reliance on external financing and could constrain strategic initiatives.

Product and Service Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Crop Protection and Seeds

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CTVA	Corteva, Inc.	primary	56.80 Bn	55.64	3.19	4.88 Bn
2	FMC	Fmc Corp	primary	1.54 Bn	-0.56	0.48	4.29 Bn
3	CBUS	Cibus, Inc.	primary	0.12 Bn	-1.16	33.91	0.00 Bn
4	AVD	American Vanguard Corp	primary	0.06 Bn	-1.54	0.13	0.27 Bn
5	BIOX	Bioceres Crop Solutions Corp.	primary	0.03 Bn	-0.39	0.10	0.17 Bn
6	GNVR	Genvor Inc	primary	0.02 Bn	-7.21	-	0.00 Bn
7	SEED	Origin Agritech LTD	primary	0.01 Bn	-	-	0.01 Bn
8	SNES	SenesTech, Inc.	primary	0.00 Bn	-0.67	1.97	0.00 Bn

Fmc FMC

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password